Loading patent…
AssigneesVitae Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH
InventorsDavid A. Claremon, Linghang Zhuang, Katerina Leftheris, Colin M. Tice, Zhenrong Xu, Yuanjie Ye, Suresh B. Singh, Salvacion Cacatian, Wei Zhao
Estimating the term…
Disclosed is a compound represented by Formula (Im1) or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Also disclosed are pharmaceutical compositions comprising the compound of Formula (Im1) or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof and methods of inhibiting 11β-HSD1 activity comprising the step of administering to a mammal in need of such treatment an effective amount of a compound of Formulas (Im1), or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
A compound of the following formula:
A method of treating a human with a disease or condition selected from Type II diabetes mellitus, obesity, glucose intolerance, hyperglycemica, hyperlipidemia, insulin resistance and dyslipidemia comprising the step of administering to the human with the disease or condition an effective amount of a compound of the following formula:
A pharmaceutical composition comprising:
A compound of the following formula:
A pharmaceutical composition comprising:
A method of treating a human with a disease or condition selected from Type II diabetes mellitus, obesity, glucose intolerance, hyperglycemica, hyperlipidemia, insulin resistance and dyslipidemia comprising the step of administering to the human with the disease or condition an effective amount of a compound of the following formula:
A monohydrate of a compound of the following formula:
A pharmaceutical composition comprising:
A method of treating a human with a disease or condition selected from Type II diabetes mellitus, obesity, glucose intolerance, hyperglycemica, hyperlipidemia, insulin resistance and dyslipidemia comprising the step of administering to the human with the disease or condition an effective amount of a monohydrate of a compound of the following formula:
A monohydrate of a compound of the following formula:
A pharmaceutical composition comprising:
A method of treating a human with a disease or condition selected from Type II diabetes mellitus, obesity, glucose intolerance, hyperglycemica, hyperlipidemia, insulin resistance and dyslipidemia comprising the step of administering to the human with the disease or condition an effective amount of a monohydrate of a compound of the following formula:
A hydrate of a compound of the following formula:
A pharmaceutical composition comprising:
A method of treating a human with a disease or condition selected from Type II diabetes mellitus, obesity, glucose intolerance, hyperglycemica, hyperlipidemia, insulin resistance and dyslipidemia comprising the step of administering to the human with the disease or condition an effective amount of a hydrate of a compound of the following formula:
A hydrate of a compound of the following formula:
A pharmaceutical composition comprising:
A method of treating a human with a disease or condition selected from Type II diabetes mellitus, obesity, glucose intolerance, hyperglycemica, hyperlipidemia, insulin resistance and dyslipidemia comprising the step of administering to the human with the disease or condition an effective amount of a hydrate of a compound of the following formula:
Dependencies are inferred from the claim text.